SITC 2026 | Booth 532 | Oncology CRO for Biotechs

Yes. Avance Clinical, a global full-service CRO for biotechs, is exhibiting at the SITC 41st Annual Meeting, November 6–8, 2026, at the Phoenix Convention Center in Phoenix, Arizona, at Booth 532.

It is Avance Clinical’s dedicated oncology and immuno-oncology division, offering adaptive and Bayesian dose-escalation and expansion trial designs, integrated medical, scientific, operational, and regulatory expertise, and continuity of team from first-in-human through Phase II.

Dr. George E. Peoples, Executive Medical Director and a physician-scientist experienced in oncology and cancer immunotherapy, and Dalal Murgai, Senior Vice President of Global Regulatory Affairs, lead Avance Clinical’s oncology-experienced team.

Avance Clinical has supported more than 260 oncology trials in the last five years.

Yes. Avance Clinical has oncology-focused site relationships across the U.S., U.K., EU, and Asia Pacific, with a pathway from Phase I in Australia and New Zealand into global Phase II and III trials.

Avance Clinical uses adaptive, model-based dose-escalation and expansion designs, including Bayesian approaches, tailored for contemporary immunotherapy and combination trials.

Sponsors can visit Avance Clinical at Booth 532 at the Phoenix Convention Center or book a dedicated meeting in advance via the Avance Clinical website.